By celf_admin
Triple Hair Expands Global Phase III Program for TH07 with Launch of 500-Patient Trial in India corporate Triple Hair Group Inc. (“Triple Hair” or the “Company”), a company specializing in the development of innovative treatments for androgenic alopecia (pattern baldness), today announced the initiation of its Phase III clinical trial in India evaluating TH07, the … Continued
By celf_admin
Triple Hair Doses First Patient in Phase III Clinical Trial in Canada for Male Androgenic Alopecia Corporate Triple Hair Group Inc. (“Triple Hair” or the “Company”), a company specializing in the development of innovative treatments for androgenic alopecia (pattern baldness), today announced that the first patient has been dosed in its Phase III clinical trial … Continued
By celf_admin
Triple Hair’s Feature in the NY Post Media Triple Hair is pleased to share that its proof-of-concept trial results have been featured in the New York Post. The article, titled “New triple-threat topical treatment fights hair loss better than finasteride and minoxidil,” highlights the promising findings from our TH-07 research- read the full article her … Continued
By celf_admin
Triple Hair Group Signs Licensing Agreement for the Brazilian Market with Aché Triple Hair Group Inc. (“Triple Hair” or the “Company”), a company specializing in the development of innovative treatments for androgenic alopecia, is pleased to announce that it has signed a licensing agreement with Aché Laboratorios Farmacêuticos S.A. (“Aché”), granting Aché exclusive rights to … Continued
By celf_admin
Triple Hair Group Strengthens Leadership Team with Appointment of Paul Sowyrda to its Board of Directors Triple Hair Group Inc. (“Triple Hair” or the “Company”), a company specializing in the development of innovative treatments for androgenic alopecia, is pleased to announce the appointment of Paul Sowyrda to its Board of Directors. Paul Sowyrda is an … Continued
By celf_admin
TH07 Clinical Study Featured in Peer-Reviewed Scientific Journal Science ABSTRACT Objectives:Androgenic alopecia (AGA) is common among men. Currently, topical minoxidil and oral finasteride are approved by the FDA for the treatment of AGA. Unfortunately, neither of them is completely effective and systemic adverse events have been reported after finasteride administration. Triple Hair Inc. has developed … Continued
By celf_admin
Triple Hair Group Enters Into Licensing Agreement with Akums for Therapy-07 in India Corporate Triple Hair Group Inc. (“Triple Hair” or the “Company”), a company specializing in the development of innovative treatments for androgenic alopecia, is pleased to announce that it has entered into a strategic partnership with Akums Drugs & Pharmaceuticals Ltd. (“Akums”), India’s … Continued
By celf_admin
Triple Hair Group Receives EMA Approval to Start Phase III Clinical Trials on its Therapy-07 Prescription Drug in Europe Corporate Triple Hair Group Inc. (“Triple Hair” or the “Company”), a company specializing in the development of innovative treatments for androgenic alopecia, is pleased to announce that it has received approval from the European Medicines Agency … Continued
By celf_admin
Triple Hair’s Feature in Le Journal de Montréal MEDIA Triple Hair is one of two startups mentioned in the latest Le Journal de Montréal article. Thank you for highlighting our achievements. Read the full article here: https://www.journaldemontreal.com/2024/06/08/dans-lil-du-quebec-inc-des-patrons-de-cae-empochent
By celf_admin
Triple Hair Group Closes $4 Million Financing Corporate, MEDIA Montréal, Québec, June 3, 2024 – Triple Hair Group Inc. (“Triple Hair” or the “Company”), a company specializing in the development of innovative treatments for androgenic alopecia, is pleased to announce that it has closed a $4 million financing with a group of investors. The main … Continued
